CENTER VALLEY, Pa., Sept. 5, 2024 /PRNewswire/ -- Odin Medical Ltd., an Olympus Corporation company, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the first cloud-based Artificial Intelligence (AI) technology designed to assist gastroenterologists in detecting suspected colorectal polyps during colonoscopy procedures, the CADDIE™ computer-aided detection (CADe) device.
In the constantly evolving, fast-paced world of AI, this innovative cloud-based technology supports doctors to improve the detection of the early signs of colorectal cancer using AI software that can be remotely updated. The flexibility, speed-to-innovation, and potential cost-savings of a cloud-based system are designed to help endoscopists provide a high level of care to patients.
"Together with Olympus, we are proud to bring this groundbreaking technology to the U.S. The cloud gives us the ability to keep hospitals up-to-date with advances in AI and gives peace of mind to doctors that they can easily access current technology for their patients," said Peter Mountney, Ph.D., CEO of Odin Vision.
Ad Statistics
Times Displayed: 11075
Times Visited: 14 Final days to save an extra 10% on Imaging, Ultrasound, and Biomed parts web prices.* Unlimited use now through September 30 with code AANIV10 (*certain restrictions apply)
CADDIE™ device improves adenomas detected per colonoscopy
A prospective, multi-center randomized controlled trial successfully demonstrated the efficacy and safety of the CADDIE device, underscoring its potential to enhance detection capabilities and patient care without increasing procedural risks or duration. The trial was conducted across eight medical centers in Europe.
"The trial shows that use of the CADDIE device improved the adenomas detected per colonoscopy, which is linked to cancer prevention.i The potential for this system to support more endoscopists in helping more patients is truly exciting," said Professor Alessandro Repici, Chairman, Department of Gastroenterology at Humanitas University & Humanitas Research Hospital, Italy, and principal investigator of the trial.
The CADDIE device works by analyzing colonoscopy video in real-time and using visual markers to alert the endoscopist to the potential presence of polyps. The endoscopist is responsible for reviewing the CADDIE™ device's suspected polyp areas and confirming the presence or absence of a polyp based on their own medical judgment.
Olympus aims to reduce the societal burden of colorectal cancer
Supporting advancements in colorectal cancer screening and detection, Olympus aims to reduce the societal burden of lives lost to colorectal cancer, which is expected to claim more than 53,000 lives in the U.S. in 2024ii and is the second-leading cause of cancer deaths among men and women in the U.S.iii Of concern is the rising incidence of colorectal cancer in people under 50, with forecasting models predicting that colorectal cancer will be the leading cause of cancer deaths in people under 50 by 2030.iv Early detection has never been more important. More than 90% of patients survive five years or more when the cancer is found at an early stage.v